Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022117 | 0.84 | RET (0.57) | HSP90AA1HSP90AB1L3MBTL1RET | |
| SCHEMBL3154912 | 0.81 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL3154918 | 0.81 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL24296015 | 0.80 | RET (0.47) | KDM4EALDH1A1L3MBTL1RETDPP4 | |
| SCHEMBL22570975 | 0.80 | RET (0.47) | KDM4EALDH1A1L3MBTL1RETDPP4 | |
| SCHEMBL16718831 | 0.80 | JAK2 (0.54) | DPP4GRM4CHRM4KCNH2 | |
| SCHEMBL16718803 | 0.80 | GRM4 (0.59) | KDM4EALDH1A1L3MBTL1DPP4GRM4 | |
| SCHEMBL2098756 | 0.79 | AVPR1A (0.45) | HSP90AA1HSP90AB1L3MBTL1RETDPP4 | |
| SCHEMBL2098753 | 0.79 | AVPR1A (0.45) | HSP90AA1HSP90AB1L3MBTL1RETDPP4 | |
| SCHEMBL3155701 | 0.79 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | DPP4, DPP8, DPP3 | HSP90AA1 4266/4885HSP90AB1 3986/4885KDM4E 458/4885 |
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | HSP90AA1 2953/4885HSP90AB1 2300/4885KDM4E 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.